HSBC Holdings plc vs Revvity Inc — how do they compare? HSBC Holdings plc trades at $100.64 (market cap $335.21B), while Revvity Inc trades at $106.58 (market cap $11.87B). The key difference: HSBC Holdings plc is far larger — about 28.2× Revvity Inc's market cap, and HSBC Holdings plc pays the higher dividend (3.79%). Which is the better fit depends on your goals.
| HSBC | RVTY | |
|---|---|---|
Market Cap | $335.21B | $11.87B |
Sector | Technology | Technology |
52-Week High | $100.61 | $117.75 |
52-Week Low | $61.30 | $82.26 |
Dividend Yield | 3.79% | 0.26% |
Enterprise Value | — | $14.36B |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $99.01, down 1.59% today but near its 52-week high of $99.47. The stock shows strong technical momentum with bullish moving averages, though oscillators suggest potential overbought conditions. Fundamentally, the bank maintains robust profitability with 30.81% net income margin and 10.89% ROE, supported by recent earnings beats and a $0.50 dividend declaration. Recent news highlights strategic moves including AI partnerships and business portfolio optimization.
HSBC presents a mixed outlook with solid fundamentals and strategic initiatives balanced against valuation concerns and regional risks. The bank's focus on AI integration and market exits could drive efficiency, but regulatory challenges and economic uncertainty pose headwinds. Analyst consensus leans cautious with 38% buy ratings, suggesting selective opportunity for long-term investors despite near-term overbought signals.
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
Trailing returns across standard periods
Latest headlines on both assets
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →